E-LIB Suche - Ergebnisse für: Gutzmer, R

1

Early recurrence in a pooled international cohort of melano..:

Mortier, L. ; Gutzmer, R. ; Atkinson, V....
EJC Skin Cancer. 2 (2024) - p. 100151 , 2024

Link: https://doi.org/10.1016/..

2

Sex differences and its impact on treatment outcomes of adv..:

Leven, A.-S. ; Peters, T. ; Rajcsanyi, L.S....
EJC Skin Cancer. 2 (2024) - p. 100167 , 2024

Link: https://doi.org/10.1016/..

3

Checkpoint inhibitor‐induced bullous pemphigoid differs fro..:

Kramer, N. ; Müller, G. ; Zierold, S....
Journal of the European Academy of Dermatology and Venereology. , 2024

Link: https://doi.org/10.1111/..

4

A phase 3 study of the efficacy, safety, and pharmacokineti..:

Long, G.V. ; Gutzmer, R. ; Haydon, A....
EJC Skin Cancer. 2 (2024) - p. 100143 , 2024

Link: https://doi.org/10.1016/..

5

Interim analysis of the multinational, post-authorisation s..:

Gutzmer, R. ; Mohr, P. ; Kähler, K....
EJC Skin Cancer. 2 (2024) - p. 100044 , 2024

Link: https://doi.org/10.1016/..

6

Early switch from run-in treatment with vemurafenib plus co..:

Livingstone, E. ; Gogas, H. ; Kandolf-Sekulovic, L....
European Journal of Cancer. 190 (2023) - p. 112941 , 2023

Link: https://doi.org/10.1016/..

7

Preferences of German and Swiss melanoma patients for toxic..:

Kähler, Katharina C. ; Hüning, S. ; Nashan, D....
Journal of Cancer Research and Clinical Oncology. 149 (2023) 13 - p. 11705-11718 , 2023

Link: https://doi.org/10.1007/..

8

What is the benefit of certification from a centre's point ..:

Rückher, J. ; Utzig, M. ; Stilgenbauer, S....
Forum. 38 (2022) 2 - p. 123-127 , 2022

Link: https://doi.org/10.1007/..

9

The effect of mogamulizumab on the malignant T cell populat..:

Gosmann, JG ; Bielefeld, A ; Schaper-Gerhardt, K..
European Journal of Cancer. 173 (2022) - p. S26 , 2022

Link: https://doi.org/10.1016/..

10

Corrigendum to 'Pembrolizumab for locally advanced and recu..:

Hughes, B.G.M. ; Munoz-Couselo, E. ; Mortier, L....
Annals of Oncology. 33 (2022) 8 - p. 853 , 2022

Link: https://doi.org/10.1016/..

11

Biomarkers of treatment benefit with atezolizumab plus vemu..:

Robert, C. ; Lewis, K.D. ; Gutzmer, R....
Annals of Oncology. 33 (2022) 5 - p. 544-555 , 2022

Link: https://doi.org/10.1016/..

12

Pembrolizumab for locally advanced and recurrent/metastatic..:

Hughes, B.G.M. ; Munoz-Couselo, E. ; Mortier, L....
Annals of Oncology. 32 (2021) 10 - p. 1276-1285 , 2021

Link: https://doi.org/10.1016/..

13

Effectiveness, safety and utilization of vismodegib in loca..:

Gutzmer, R. ; Schulze, H.‐J. ; Hauschild, A....
Journal of the European Academy of Dermatology and Venereology. 35 (2021) 8 - p. 1678-1685 , 2021

Link: https://doi.org/10.1111/..

14

Vorgehen bei kutanem Plattenepithelkarzinom:

das Komitee "Epitheliale Tumore" der Arbeitsgemeinschaft Dermatologische Onkologie ; Leiter, U. ; Gutzmer, R....
Der Onkologe. 27 (2021) 6 - p. 579-586 , 2021

Link: https://doi.org/10.1007/..

15

Protective measures for patients with advanced cancer durin..:

Ivanyi, P. ; Park-Simon, T. ; Christiansen, H....
Clinical & Experimental Metastasis. 38 (2021) 3 - p. 257-261 , 2021

Link: https://doi.org/10.1007/..